A real-world analysis of patients MBC + mutESR1 tx with elacestrant. Time to discontinue (TTD) and next treatment (TTNT) were similiar to PFS in EMERALD despite recieving elacestrant beyond 2L
#SABCS24 @oncoalert.bsky.social
#SABCS24 @oncoalert.bsky.social
December 11, 2024 at 2:21 PM
A real-world analysis of patients MBC + mutESR1 tx with elacestrant. Time to discontinue (TTD) and next treatment (TTNT) were similiar to PFS in EMERALD despite recieving elacestrant beyond 2L
#SABCS24 @oncoalert.bsky.social
#SABCS24 @oncoalert.bsky.social
Elacestrant is being studied in combo with LOTS of partners. Side effects are generally the same as when these drugs are paired with currently available endocrine agents. #SABCS24
December 11, 2024 at 2:36 PM
Elacestrant is being studied in combo with LOTS of partners. Side effects are generally the same as when these drugs are paired with currently available endocrine agents. #SABCS24
12/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
January 15, 2025 at 1:36 AM
12/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease: A discussion with @oncbrothers.bsky.social and @ptarantinomd.bsky.social. #BCSM
www.targetedonc.com/view/elacest...
www.targetedonc.com/view/elacest...
Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 analysis, which identified the duration of prior CDK4/6 inhibitor (CDK4/6i) th...
www.targetedonc.com
December 5, 2024 at 8:34 PM
Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease: A discussion with @oncbrothers.bsky.social and @ptarantinomd.bsky.social. #BCSM
www.targetedonc.com/view/elacest...
www.targetedonc.com/view/elacest...
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
January 15, 2025 at 1:46 AM
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
Elacestrant (Orserdu) monotherapy has people with ESR1 mutation who do really well and some who have rapid progression. Why?? IDK but we need biomarkers to figure this out!! #SABCS24
December 11, 2024 at 2:14 PM
Elacestrant (Orserdu) monotherapy has people with ESR1 mutation who do really well and some who have rapid progression. Why?? IDK but we need biomarkers to figure this out!! #SABCS24
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
January 15, 2025 at 1:28 AM
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer @hoperugo.bsky.social @ucsfcancer.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #medtwitter #oncology www.onclive.com/view/elacest...
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
www.onclive.com
December 11, 2024 at 6:46 PM
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer @hoperugo.bsky.social @ucsfcancer.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #medtwitter #oncology www.onclive.com/view/elacest...
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025
@sabcs.bsky.social
oncodaily.com/industry/ela...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Menarini #Elacestrant #ORSERDU #BreastCancer #SABCS2025
@sabcs.bsky.social
oncodaily.com/industry/ela...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Menarini #Elacestrant #ORSERDU #BreastCancer #SABCS2025
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025 - OncoDaily
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025 / Breast Cancer, cancer, elacestrant,
oncodaily.com
December 10, 2025 at 10:16 PM
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025
@sabcs.bsky.social
oncodaily.com/industry/ela...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Menarini #Elacestrant #ORSERDU #BreastCancer #SABCS2025
@sabcs.bsky.social
oncodaily.com/industry/ela...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Menarini #Elacestrant #ORSERDU #BreastCancer #SABCS2025
Menarini Group Unveils Promising Data From Elacestrant and Capivasertib Study at ASCO 2026#Italy#Elacestrant#Florence#Menarini_Group#Capivasertib
Menarini Group Unveils Promising Data From Elacestrant and Capivasertib Study at ASCO 2026
Menarini Group has announced promising early results from the ELEVATE study evaluating elacestrant with capivasertib for ER+, HER2- metastatic breast cancer, showcased at ASCO 2026.
third-news.com
May 28, 2026 at 4:51 PM
Menarini Group Unveils Promising Data From Elacestrant and Capivasertib Study at ASCO 2026#Italy#Elacestrant#Florence#Menarini_Group#Capivasertib
Next case. Elacestrant monotherapy was chosen by the audience, prob because of the patient’s strong preference for oral therapy - and data from EMERALD backs this up. #SABCS24
December 11, 2024 at 10:58 PM
Next case. Elacestrant monotherapy was chosen by the audience, prob because of the patient’s strong preference for oral therapy - and data from EMERALD backs this up. #SABCS24
Menarini Group Unveils Promising ELEVATE Study Data on Elacestrant and Capivasertib in Breast Cancer Treatment#Italy#Menarini#Elacestrant#Florence#Capivasertib
Menarini Group Unveils Promising ELEVATE Study Data on Elacestrant and Capivasertib in Breast Cancer Treatment
Menarini Group presents exciting preliminary data on the efficacy and safety of Elacestrant combined with Capivasertib for ER+/HER2- metastatic breast cancer at ASCO 2026.
third-news.com
May 29, 2026 at 9:17 PM
Menarini Group Unveils Promising ELEVATE Study Data on Elacestrant and Capivasertib in Breast Cancer Treatment#Italy#Menarini#Elacestrant#Florence#Capivasertib
Donald is a brilliant friend and collaborator. He was directly involved in the discovery of elacestrant and lasofoxifene for MBC. Believe him.
March 9, 2025 at 3:03 AM
Donald is a brilliant friend and collaborator. He was directly involved in the discovery of elacestrant and lasofoxifene for MBC. Believe him.
Menarini Group Reveals Promising ELEVATE Study Results on Elacestrant and Capivasertib for ER+, HER2- Breast Cancer#Italy#Menarini#Elacestrant#Florence#Capivasertib
Menarini Group Reveals Promising ELEVATE Study Results on Elacestrant and Capivasertib for ER+, HER2- Breast Cancer
Menarini Group provides new insights into the ELEVATE study, showcasing the potential of elacestrant and capivasertib for treating ER+, HER2- metastatic breast cancer. Key findings will be showcased at ASCO 2026.
third-news.com
May 29, 2026 at 3:48 PM
Menarini Group Reveals Promising ELEVATE Study Results on Elacestrant and Capivasertib for ER+, HER2- Breast Cancer#Italy#Menarini#Elacestrant#Florence#Capivasertib
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer. @bidmc-cancercenter.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #oncology
www.onclive.com/view/dr-lloy...
www.onclive.com/view/dr-lloy...
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.
www.onclive.com
December 13, 2024 at 3:09 AM
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer. @bidmc-cancercenter.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #oncology
www.onclive.com/view/dr-lloy...
www.onclive.com/view/dr-lloy...
#MedSky🧪 #Oncosky #pharmasky #skyRx #publichealth @NICE final draft guidance recommends elacestrant (KORSERDU ) for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic #breastcancer with an activating ESR1 mutation.
December 20, 2024 at 5:32 AM
#MedSky🧪 #Oncosky #pharmasky #skyRx #publichealth @NICE final draft guidance recommends elacestrant (KORSERDU ) for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic #breastcancer with an activating ESR1 mutation.
Another all oral option, based on BYLieve could be alpelisib + letrazole. What about off label use of Elacestrant + CDK4/6 inhibitor ?? This is being looked at in EMBER3 (imlunestrant) and ELEVATE (Elacestrant) #SABCS24
December 11, 2024 at 10:58 PM
Another all oral option, based on BYLieve could be alpelisib + letrazole. What about off label use of Elacestrant + CDK4/6 inhibitor ?? This is being looked at in EMBER3 (imlunestrant) and ELEVATE (Elacestrant) #SABCS24
I don't want to think about how long it took to make this... Elacestrant (racemic). £700 for 10mgs and I finally have 1.5g. Do I finish the PhD or just sell it and make a run for it?
March 25, 2025 at 7:25 AM
I don't want to think about how long it took to make this... Elacestrant (racemic). £700 for 10mgs and I finally have 1.5g. Do I finish the PhD or just sell it and make a run for it?
Getting Elacestrant combos approved and thus accessible is going to be a big deal for many MBC patients.
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer @sabcs.bsky.social #SABCS25 #bcsm
www.onclive.com/view/elacest...
www.onclive.com/view/elacest...
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer | OncLive
Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.
www.onclive.com
December 30, 2025 at 6:44 AM
Getting Elacestrant combos approved and thus accessible is going to be a big deal for many MBC patients.
Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer. @uthealthsa.bsky.social @uthealthsamda.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #oncology
www.onclive.com/view/dr-kakl...
www.onclive.com/view/dr-kakl...
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.
www.onclive.com
December 11, 2024 at 6:45 PM
Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer. @uthealthsa.bsky.social @uthealthsamda.bsky.social @sabcs.bsky.social #SABCS24 #bcsm #oncology
www.onclive.com/view/dr-kakl...
www.onclive.com/view/dr-kakl...
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
January 15, 2025 at 1:45 AM
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
Great news!
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
We respond to SMC decision recommending elacestrant & capivasertib with fulvestrant
Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
breastcancernow.org
September 8, 2026 at 8:39 AM
Great news!
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...